| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 07/03/2025 | 22:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 07/03/2025 | 22:03 | Edgar (US Regulatory) | Form 3/A - Initial statement of beneficial ownership of securities: [Amend] | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 06/03/2025 | 22:05 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 03/03/2025 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 26/02/2025 | 22:14 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 25/02/2025 | 15:00 | PR Newswire (US) | BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 24/02/2025 | 22:05 | PR Newswire (US) | BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 24/02/2025 | 19:54 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 19/02/2025 | 22:05 | PR Newswire (US) | BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 13/02/2025 | 20:14 | Edgar (US Regulatory) | Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 05/02/2025 | 15:00 | PR Newswire (US) | BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 13/01/2025 | 18:00 | PR Newswire (US) | BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 06/01/2025 | 14:30 | PR Newswire (US) | BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 16/11/2024 | 16:45 | PR Newswire (US) | BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 06/11/2024 | 14:00 | PR Newswire (US) | BioMarin to Participate in Three Upcoming Investor Conferences | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 31/10/2024 | 20:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 29/10/2024 | 21:03 | PR Newswire (US) | BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 24/10/2024 | 13:00 | GlobeNewswire Inc. | Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 16/10/2024 | 14:30 | PR Newswire (US) | BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 30/09/2024 | 22:29 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 18/09/2024 | 14:00 | PR Newswire (US) | BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 04/09/2024 | 19:00 | PR Newswire (US) | BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 04/09/2024 | 13:30 | PR Newswire (US) | BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 29/08/2024 | 14:00 | PR Newswire (US) | BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 21/08/2024 | 14:30 | PR Newswire (US) | BioMarin Announces New R&D and Business Development Leadership | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 19/08/2024 | 15:00 | PR Newswire (US) | BioMarin to Host 2024 Investor Day on September 4th in New York | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 05/08/2024 | 22:03 | PR Newswire (US) | BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 05/08/2024 | 22:01 | PR Newswire (US) | BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 24/07/2024 | 22:05 | PR Newswire (US) | U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
| 23/07/2024 | 14:00 | PR Newswire (US) | BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
